Illumina, Inc. (NASDAQ:ILMN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have been given a consensus recommendation of “Moderate Buy” by the twenty-three ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation, twelve have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $151.05.

A number of research firms have recently commented on ILMN. Robert W. Baird upped their price objective on shares of Illumina from $119.00 to $124.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Barclays raised shares of Illumina from an “underweight” rating to an “equal weight” rating and set a $125.00 price target on the stock in a research note on Wednesday, August 14th. JPMorgan Chase & Co. lowered their price objective on shares of Illumina from $130.00 to $125.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Evercore ISI cut their target price on Illumina from $195.00 to $175.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 11th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $242.00 price target on shares of Illumina in a research report on Wednesday, August 14th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ILMN. WCM Investment Management LLC increased its holdings in Illumina by 2,232.3% during the 1st quarter. WCM Investment Management LLC now owns 3,377,221 shares of the life sciences company’s stock worth $463,760,000 after purchasing an additional 3,232,418 shares during the last quarter. Primecap Management Co. CA grew its position in shares of Illumina by 462.5% during the second quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock worth $253,514,000 after buying an additional 1,997,010 shares in the last quarter. Capital World Investors bought a new stake in shares of Illumina in the fourth quarter worth $271,753,000. Norges Bank acquired a new stake in shares of Illumina in the 4th quarter valued at about $264,636,000. Finally, Millennium Management LLC raised its stake in Illumina by 305.0% during the second quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock valued at $155,067,000 after buying an additional 1,118,747 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of ILMN opened at $129.52 on Tuesday. Illumina has a 1 year low of $89.00 and a 1 year high of $148.19. The company’s 50 day simple moving average is $123.79 and its 200 day simple moving average is $120.61. The company has a market capitalization of $20.63 billion, a price-to-earnings ratio of -15.89 and a beta of 1.15. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.11.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.24. The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a positive return on equity of 3.08% and a negative net margin of 68.73%. The business’s revenue was down 5.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.32 earnings per share. On average, sell-side analysts predict that Illumina will post 3.62 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.